ISSN 0976 - 8157

www.pharmacie-globale.info

Indexing & Abstracting: DOAJ, Index Copernicus, Chemical Abstract Services (CAS), EBSCO Publishing, Ulrich's Serial database, NewJour, GFMER, Science Central, Libraries Directory, IRNEM, Biblioteca, Open J-gate...........
Home

New technology to tackle treatment-resistant cancers

E-mail Print PDF

New technology to tackle treatment-resistant cancers

Free-flowing cancer cells have been mapped with unprecedented accuracy in the bloodstream of patients with prostate, breast and pancreatic cancer, using a brand new approach, in an attempt to assess and control the disease as it spreads in real time through the body, and solve the problem of predicting response and resistance to therapies.

In comparison to a previous generation of systems, the researchers state their test showed a significantly greater number of high-definition circulating tumour cells (HD-CTCs), in a higher proportion of patients, by using a computing-intensive method that enables them to look at millions of normal cells and find the rare cancer cells among them.

Their results published in IOP Publishing's journal Physical Biology, could help reveal the mechanisms behind the spread of solid tumours from one organ or tissue to another - mechanisms that have, until now, remained a mystery.

Dr Jorge Nieva, an oncologist at Billings Clinic leading the study, said: "This technology will allow scientists to move away from mouse and cell culture systems and speed the delivery of cures for cancer in people. This is the technology we have been waiting for to solve the problem of resistance to chemotherapy drugs."

Senior technology author of the study, Professor Peter Kuhn, said: "In the future, our fluid biopsy can effectively become the companion to the patient for life. If we can assess the disease in real time, we can make quantitative treatment decisions in real time. These decisions include predictive decisions about therapeutic response, diagnostic decisions and prognostic decisions about outcome."

The researchers, based at the Scripps Physics Oncology Center in La Jolla, California, were able to find five or more CTCs in each milliliter of blood in 80% of the 20 patients they tested with prostate cancer; 70% in the 30 patients with breast cancer; and 50% in the 18 patients with pancreatic cancer.

The authors also report that their test showed significantly better results when compared with the commercial test, CellSearch®, which uses a slightly less accurate approach which effectively reduces the sample from approximately 50 million cells to just 5,000 before conducting fluorescent imaging, meaning important cells you wish to study could be lost.

(worldpharmanews.com)

Last Updated on Tuesday, 02 February 2016 08:51  

LATEST NEWS


Editorial Board

Who's Online

We have 48 guests online

Statistics Counter

joomla visitor

Polls

Do you think pharmaceutical companies should spend more on educating physicians about their products?
 

Social Widgets